23.16 0.00 (0.00%)
After hours: 4:00PM EST
Previous Close | 24.21 |
Open | 24.31 |
Bid | 23.25 x 1000 |
Ask | 23.31 x 800 |
Day's Range | 23.16 - 24.31 |
52 Week Range | 5.97 - 26.98 |
Volume | 208,135 |
Avg. Volume | 235,990 |
Market Cap | 757.772M |
Beta (5Y Monthly) | 1.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.86 |
Earnings Date | Mar 09, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.00 |
Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System ("SDS") packaged with the company’s PROPEL® Mini (mometasone furoate) Sinus Implant. The combined packaging of the SDS with PROPEL Mini received premarket approval ("PMA") by the U.S. Food and Drug Administration ("FDA") which follows PMA for the Straight Delivery System received in July 2020.
Intersect ENT to Participate in Upcoming Investor Conferences